JWCTF
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.68 | $174M | -$78M |
| 2025 Q2 | -0.64 | $106M | -$8M |
| 2024 Q4 | -0.84 | $71M | -$148M |
| 2024 Q2 | -0.58 | $87M | -$191M |
| 2023 Q4 | -0.94 | $86M | -$166M |
| 2023 Q2 | -0.93 | $88M | -$245M |
| 2022 Q4 | -1.01 | $80M | -$216M |
| 2022 Q2 | -1.05 | $66M | -$398M |